Register for Clinical Trials authorized since 2016- Updated on 3rd OCT 2024
| SN | CTA # | Title | Date of initial Authorization | Principal Investigator | Institution | Sponsor | Status (ongoing, terminated, closed out, suspended or terminated as a result of an inspection | Duration of the trial | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | 0001 | Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-center, parallel-group, two arm randomized placebo controlled superiority trial. | 4/4/2016 | Assoc Prof. Robert Opoka Opoka | Department of Pediatrics and Child Health, MUCHS | Liverpool School of Tropical Medicine (LSTM) | Closed Out | ||
| 2. | 0002 | Doxycycline for the treatment of nodding syndrome: A phase II, randomized placebo controlled trial. | 4/5/2016 | Assoc Prof. Richard Idro | Department of Pediatrics and Child Health, MUCHS | Ongoing | |||
| 3. | 0003 | Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability, and Anti-Retroviral Activity of GSK 1349572 (Dolutegravir), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents. (IMPAACT P1093) | 5/19/2016 | Dr. Maxensia Owor | Makerere University – John Hopkins University (MUJHU) Care Ltd. | United States National Institute of Health | Ongoing | ||
| 4. | 0004 | Prevention of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 3) | 8/9/2016 | Prof. Moses Kamya | MU-UCSF | Closed Out | |||
| 5. | 0005 | A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS -9883/ Emtricitabine/Tenofovir Alafenamide (GS - 9883/F/TAF) from Elvitegravir /Cobicistat /Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF), or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumerate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women. | 5/11/2016 | Dr. Cissy Kityo Mutuluza | Joint Clinical Research Centre | Gilead Sciences | Ongoing | ||
| 6. | 0006 | A randomized trial of dolutegravir (DTG)-based antiretroviral therapy vs standard of care (SOC) in children with HIV infection starting first line or switching to second line ART. (ODYSSEY PENTA 20) | 7/15/2016 | Dr. Cissy Kityo Mutuluza | Joint Clinical Research Centre | Closed out | |||
| 7. | 0007 | Pharmacokinetics of efavirenz 400 mg once daily during pregnancy in HIV -1 infected women. | 7/7/2016 | Prof.Mohammed Lamorde | Infectious Diseases Institute | Closed out | |||
| 8. | 0008 | Investigation of rheumatic AF Treatment Using Vitamin K antagonists, rivaroxaban or aspirin Studies. (INVICTUS) | 12/12/2016 | Dr. Emmy Okello | Uganda Heart Institute | Population Health Research Institute | Closed-out | ||
| 9. | 0009 | A Multi-center, Phase 3B Open-label Follow-up trial to assess the continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women. (MTN 025) | 9/5/2016 | Dr. Brenda Gati Mirembe | Makerere University – John Hopkins University (MUJHU) R Care Ltd. | Division of AIDS(DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), US National Institute of Health (NIH) | Closed out | ||
| 10. | 0010 | A Multi-country, prospective, clinical safety study of subjects exposed to the candidate Ebola vaccines Ad26.ZEBOV and/or MVA –BN-Filo. | 9/2/2016 | Prof. Pontiano Kaleebu | The Medical Research Council/Uganda Virus Research Institute (MRC/UVRI) | Janssen Vaccine | Ongoing | ||
| 11. | 0011 | A Pharmacokinetic Evaluation of Increased Dose Levonorgestrel Implant and Efavirenz-Based Antiretroviral Therapy In HIV-Infected Women. | 3/10/2017 | Dr. Mohammed Lamorde | Infectious Diseases Institute | Ongoing | |||
| 12. | 0012 | A multicenter, open label, randomized, multiple dose, two period crossover, bioequivalence study of Liposomal Amphotericin B injection (Cipla Ltd., India) and AmBisome® Liposome for injection (Gilead life sciences, USA ) in adult patients with fungal infections. | 11/1/2016 | Dr. Henry Mugerwa | Joint Clinical Research Centre | Closed out | |||
| 13. | 0013 | A Follow-Up Open Label Trial to Assess The Continued Safety of and Adherence to the Dapivirine (25mg) Vaginal Ring-004 in Healthy HIV-Negative Women (Phase IIIb) | 10/10/2016 | Dr. Sylvia Kusemererwa | The Medical Research Council/Uganda Virus Research Institute (MRC/UVRI) | Closed-out | |||
| 14. | 0014 | Strategy for Maintenance of HIV Suppression with Elvitegravir + Darunavir +Ritonavir in Children. (SMILE PROTOCOL) | 2/6/2017 | Dr. Victor Musiime | Joint Clinical Research Centre | PENTA Foundation | Amended to CTA0065 | ||
| 15. | 0015 | Defining the Molecular profile of Breast Cancer in Uganda and its Clinical Implications | 3/2/2017 | Dr. Jackson Orem | Uganda Cancer Institute | GSK | Closed Out | 36 Months | |
| 16. | 0016 | Optimizing Hydroxyurea Therapy in Children with Sickle Cell Anemia in Malaria Endemic Areas : The NOHARM Maximum Tolerated Dose (MTD) Extension Study | 3/28/2017 | Dr. Robert Opika Opoka | Global Health Uganda / Pediatric Department, Mulago Hospital | Doris Duke Charitable Foundation | Ongoing | ||
| 17. | 0017 | The effect of modified F-75 on diarrhea in the treatment of children with severe acute malnutrition. | 1/31/2017 | Dr. Elizabeth Kiboneka | Mwana Mugimu Nutrition Unit, Mulago Hospital | University of Copenhagen | Terminated | ||
| 18. | 0018 | A Phase 2/3 , Open Label Study of the Pharmacokinetics , Safety, and Antiviral Activity of the GS-9883/ Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) in HIV-1 infected Virologically Suppressed Adolescents and Children | 3/17/2017 | Dr. Eva Natukunda | Joint Clinical Research Centre | Gilead Sciences | Ongoing | ||
| 19. | 0019 | Anti-retroviral therapy for acute HIV infection | 2/15/2018 | Dr. Francis Kiweewa | Makerere University Walter Reed Project. | Henry M Jackson Foundation, United States Military HIV Research Program | Closed out | 24 Months | |
| 20. | 0021 | An open label phase I clinical trial to evaluate the effect of late boost on HIV-uninfected vaccines from EV06 trial | 3/10/2017 | Prof. Pontiano Kaleebu | The Medical Research Council/Uganda Virus Research Institute (MRC/UVRI) | Henry M Jackson Foundation, PEPFAR | Closed out | ||
| 21. | 0022 | Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans (CREOLE) | 5/31/2017 | Dr. Mondo Charles Kiiza | St. Francis Hospital Nsambya | University of Abuja | TBC | 36 Months | |
| 22. | 0023 | Phase 1 Safety and Pharmacokinetic Study of Maraviroc in HIV-1- Exposed Infants at Risk of Acquiring HIV-I Infection | 6/14/2017 | Dr. Jesca Nakibuuka | MU-JHU Care Ltd. | Division of AIDS (DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), US National Institute of Health (NIH) | Withdrawn | 28 Months | |
| 23. | 0024 | Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial | 4/26/2017 | Dr. Cissy Kityo Mutuluuza | Joint Clinical Research Centre | Centers for Disease Control and Prevention (CDC) in collaboration with AIDS Clinical Trials Group (ACTG) | Closed-out | ||
| 24. | 0025 | An international multi-center controlled clinical trial to evaluate 1200mg and 1800mg rifampicin daily in the reduction of treatment duration for pulmonary tuberculosis from 6 months to 4 months (Rifashort) | 6/14/2017 | Dr. Daniel Atwine | Epicentre - Mbarara Research Base | St George University of London | Ongoing | 36 Months | |
| 25. | 0026 | Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis among Women at High Risk for HIV infection in Kampala, Uganda | 3/29/2017 | Prof. Janet Seeley | The Medical Research Council/Uganda Virus Research Institute (MRC/UVRI) | London School of Hygiene and Tropical Medicine | Closed-out | ||
| 26. | 0027 | The evaluation of a standard treatment regimen of anti-tuberculosis drugs for patients with MDR-TB (STREAM) | 5/23/2017 | Dr. Bruce Kirenga | Makerere University – Lung Institute (MLI) | The International Union Against the TB and Lung Disease (IUATLD) | Closed-out | 60 Months | |
| 27. | 0028 | Assessing the tolerability and safety of single low dose Primaquine in African Children with Acute Uncomplicated Falciparum Malaria and Glucose-6-Phoasphate Dehydrogenase Deficiency. | 6/22/2017 | Dr. Peter Olupot-Olupot | Mbale Clinical Research Institute (MCRI) | Mahidol Oxford Research Unit-University of Oxford | Ongoing | 60 Months | |
| 28. | 0029 | First line Antimicrobials in Children with complicated Severe Acute Malnutrition. (FLACSAM) | 6/22/2017 | Dr. Peter Olupot-Olupot | Mbale Clinical Research Institute (MCRI) | Oxford University | Ongoing | 36 Months | |
| 29. | 0030 | IMPAACT 2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir Containing versus Efavirenz Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants. | 9/29/2017 | Dr. Deo Wabwire | MU-JHU Care Ltd. | Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID) | Closed-out | 48 Months | |
| 30. | 0031 | Randomized clinical trial evaluating sertraline plus fluconazole verses fluconazole alone for pre-emptive treatment of asymptomatic cryptococcal antigenemia in HIV-Infected persons living with AIDS. | 8/11/2017 | Dr. David Meya | Infectious Diseases Institute | Closed-out | 48 Months | ||
| 31. | 0032 | IMPAACT 2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir –Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1 Infected Pregnant Women and their Infants | 10/20/2017 | Dr. Violet Korutaro | Baylor College of Medicine Children’s Foundation Uganda | Division of AIDS(DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), US National Institute of Health (NIH) | Ongoing | 48 Months | |
| 32. | 0033 | HPTN084: A Phase 3 Double Blind Safety and Efficacy Study of Long Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV- Uninfected Women. | 10/13/2017 | Dr. Clemensia Nakabiito | MU-JHU Care Ltd. | Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Health (NIH), | Ongoing | 60 Months | |
| 33. | 0034 | A Randomized, blinded non-inferiority trial on the immunogenicity and safety of fractional doses of yellow fever vaccines (YEFE) | 10/4/2017 | Dr. Maria Loiuse Namulwana | Epicentre - Mbarara Research Base | Rebecca Grais, Director Research Epicenter | Closed out | 48 Months | |
| 34. | 0035 | Randomized Trial to Prevent Vascular Events in HIV-REPRIEVE. Protocol No: A5332 | 9/27/2017 | Prof. Cissy Kityo Mutuluuza | Joint Clinical Research Centre | Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Health (NIH), | Closed Out | 96 Months | |
| 35. | 0036 | Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses | 12/11/2017 | Dr Cissy Kityo | Joint Clinical Research Centre | National Institute of Allergy and Infectious Diseases (NIAID) | Closed-out | 18 Months | |
| 36. | 0037 | A Phase II interventional multi-center randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersible Formulation in the combination given once daily for 1,2 and 3 days to adults and children with uncomplicated Plasmodium Falciparum Malaria. | 3/9/2018 | Dr. Adoke Yeka | Infectious Diseases Research Collaboration | Novartis Pharma AG | Closed Out | 36 Months | |
| 37. | 0038 | A Phase II interventional multi-center randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersible Formulation in the combination given once daily for 1,2,and 3 days to adults and children with uncomplicated Plasmodium Falciparum Malaria | 1/10/2018 | Dr. Sylvia Kusemererwa | MRC/UVRI | Novartis Pharmaceuticals | Closed-out | 36 Months | |
| 38. | 0039 | Optimizing iron status while minimizing morbidity in HIV-Infected Ugandan Children | 1/3/2018 | Dr. Victor Musiime | Joint Clinical Research Centre | University of Minnesota Msonic Cross-Departmental Grants for Children’s Health Research | Ongoing | 36 Months | |
| 39. | 0040 | An open Label Phase III Randomized Controlled Multicenter Non inferiority Trial to compare Efficacy and Safety of Miltefosine and Paramomycin with Sodium Stigbogluconate and Paramomycin combination for the treatment of Primary Visceral Leishmaniasis (VL) patients in East Africa. | 1/22/2018 | Prof. Joseph Olobo | Department of Immunology and Molecular Biology, Makerere University | Drugs For Neglected Diseases Initiative (DNDi) | Closed out | ||
| 40. | 0041 | Testing the ability of a microbiome-focused intervention to reduce HIV susceptibility in Ugandan men. Protocol No: TmHIV-01 | 10/17/2017 | Dr. Bernard S. Bagaya | UVRI-IAVI HIV Vaccine Program | Canadia Institute of Health Research (CIHR) | Ongoing | 31 Months | |
| 41. | 0042 | Dolutegravir in Pregnant HIV Mother and their Neonates (DOLPHIN-2) | 12/12/2017 | Dr. Mohammed Lamorde | Infectious Diseases Institute | University of Liverpool | Closed Out | ||
| 42. | 0043 | A Pilot Study of Nelfinavir for the Treatment of Kaposi’s Sarcoma (AmC 098). | 10/16/2018 | Dr. Jackson Orem | Uganda Cancer Institute | AIDS Malignancy Consortium (AMC) | Ongoing | 36 Months | |
| 43. | 0044 | A phase 2a Crossover Trial to Evaluate the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population. | 7/9/2018 | Dr. Carolyne Agwau Akello | MU-JHU Research Collaboration | Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Health (NIH) | Ongoing | 36 Months | |
| 44. | 0045 | Steady-state pharmacokinetics of Efavirenz (Stocrin) 400 mg once daily in the presence of rifampicin and isoniazid (Rifinah or the local generics). Protocol SSAT062 | 1/3/2018 | Dr. Mohammed Lamorde | Infectious Diseases Institute | St Stephens' AIDS Trust, London | Closed out | 24 Months | |
| 45. | 0046 | HIV Self-testing to empower Prevention Choices in Sex workers. | 1/3/2018 | Dr. Andrew Mujugira | Infectious Diseases Institute | Forgaty International Center | Ongoing | 9 Months | |
| 46. | 0047 | A Randomized, Double-Blind, Efficacy and Safety Study of Azilsartan Medoxomil Treatment and Withdrawal, followed by Open-Label Extension, in Children 6 to Less Than 18 Years of Age with Hypertension . | N/A | Dr. Henry Mugerwa | Joint Clinical Research Center | Rejected | 58 Months | ||
| 47. | 0048 | Simplified Isoniazid Preventive Therapy (SPIRIT) Strategy to reduce TB burden | 11/8/2018 | Prof. Moses Kamya | Infectious Diseases Research Collaboration | National Institute of Allergy and Infectious Diseases (NIAID) | Ongoing | 36 Months | |
| 48. | 0049 | A phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women. (HPTN 084) | 4/4/2018 | Dr. Patricia Nahirya Ntege | Baylor College of Medicine Children’s Foundation | Division of AIDS(DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), US National Institute of Health (NIH) | Ongoing | 54 Months | |
| 49. | 0050 | A Phase 2, multicenter, randomized open-label, dose escalation study to determine safety of single (QD) and multiple (3 QD) doses of KAE609, given to adults with uncomplicated Plasmodium falciparum malaria | 3/6/2018 | Dr. Henry Mugerwa | Joint Clinical Research Centre | Novartis Pharma AG | Closed out | 18 Months | |
| 50. | 0051 | A Phase 2, multicenter, randomized open-label, dose escalation study to determine safety of single (QD) and multiple (3 QD) doses of KAE609, given to adults with uncomplicated Plasmodium falciparum malaria | 2/28/2018 | Dr. Stephen Asiimwe | Kabwohe Clinical Research Centre | Novartis Pharma AG | Closed Out | 18 Months | |
| 51. | 0052 | A Phase 2, Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)ide Reverse Transcriptase Inhibitor-Containing Regimen with Nucloes(t)ide Transcriptase Inhibitor Resistant Virus, Followed by Continued Treatment with a GS-9131+Bictegravir+Darunavir+Ritonavir Regimen. Protocol Number: GS-US-442-4148 | 2/6/2018 | Dr. Cissy Kityo Mutuluuza | Joint Clinical Research Centre | Gilead Sciences | Ongoing | 30 Months | |
| 52. | 0053 | HIV Self-Testing and PrEP to Increase Testing and Prevention Uptake among Male Partners and improve postpartum ART Use in PMTCT B+ Programs in Uganda | 1/3/2018 | Professor Elly Katabira | Infectious Diseases Institute | US National Institute of Mental Health | Closed out | ||
| 53. | 0054 | Impact of Concurrent Initiation of DMPA Contraception and Tenofovir PrEP on Bone Loss in Young Women. | 4/17/2018 | Professor Elly Katabira | Infectious Diseases Institute | University of Washington, | Ongoing | 42 Months | |
| 54. | 0055 | A Pharmacokinetic Evaluation of Etonogestrel Implant in HIV-Infected Women on Darunavir Versus Rilpivirine-Based Antiretroviral Therapy. (DRIVE-1) | 6/26/2018 | Prof. Mohammed Lamorde | Infectious Diseases Institute | Infectious Diseases Institute | Closed Out | 24 Months | |
| 55. | 0056 | A Pharmacokinetic Evaluation of Levonorgestrel Implant in HIV-Infected Women on Darunavir versus Rilpivirine-based Antiretroviral Therapy. (DRIVE-2) | 6/27/2018 | Prof. Mohammed Lamorde | Infectious Diseases Institute | Infectious Diseases Institute | Closed Out | 24 Months | |
| 56. | 0057 | A Phase 2, multicenter, randomized open-label, dose escalation study to determine safety of single (QD) and multiple (3 QD) doses of KAE609, given to adults with uncomplicated Plasmodium falciparum malaria. | 3/1/2018 | Dr. Adoke Yeka | Infectious Diseases Research Collaboration | Novartis | Closed Out | 18 Months | |
| 57. | 0058 | A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV Uninfected Women | 4/4/2018 | Dr. Juliet Mpendo | Uganda Virus Research Institute-International AIDS Vaccine Initiative | Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Health (NIH) | Ongoing | 56 Months | |
| 58. | 0060 | Integrated PrEP and ART delivered in Ugandan public health clinics to improve HIV and ART outcomes for HIV serodiscordant couples. | 6/21/2018 | Prof. Elly Katabira | Infectious Diseases Institute | University of Washington | Ongoing | ||
| 59. | 0061 | High-Dose Intravenous Rifampicin to Improve Survival of Tuberculosis Meningitis: A phase II open-label randomized controlled trial (RifT Study). | 6/18/2018 | Dr. David B. Meya | Infectious Diseases Institute | Infectious Diseases Institute | Closed Out | 36 Months | |
| 60. | 0062 | IMPAACT 2009: Pharmacokinetics, Feasibility, Acceptability and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants. | 6/22/2018 | Dr. Clemensia Nakabiito | MUJHU Research Collaboration | National Institute of Allergy and Infectious Diseases (NIAID) | Closed Out | 9 Months | |
| 61. | 0063 | EMaBS TB Vaccine Study: Open label, dose escalation and age de-escalation for ChAdox1 85A in Ugandan adults and adolescents, followed by a Phase IIa randomized, open-label trial among adolescents comparing ChAdOx1 85A prime followed by MVA85A boost versus BCG re-vaccination. | 7/20/2018 | Prof. Alison Elliot | MRC/UVRI and LSHTM Uganda Research Unit | University of Oxford Clinical Trials and Research Governance Joint Research Office | Ongoing | 30 Months | |
| 62. | 0064 | High Dose AMBISOME on a fluconazole backbone for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: A Phase 3 Randomized Non- Inferiority Trial (AMBITION-CM). | 6/22/2018 | Dr. David Meya | Infectious Diseases Institute | London School of Hygiene and Tropical Medicine (LSHTM) | Closed-out | 48 Months | |
| 63. | 0065 | A Phase 2/3 Multi-center, Open-label, Randomized study evaluating the Safety and Anti-viral effect of once daily integrase inhibitor administered with Darunavir/ritonavir (DRV/r) compared to current Standard of Care (SOC) antiretroviral therapy in HIV-1 infected, virologically suppressed Pediatric participants. | 6/22/2018 | Dr. Victor Musiime | Joint Clinical Research Centre | PENTA Foundation | Closed Out | 72 Months | |
| 64. | 0066 | Children with HIV in Africa - Pharmacokinetics and Acceptability of Simple Second-line Anti-Retroviral Regimens. | 7/29/2018 | Dr. Victor Musiime | Joint Clinical Research Centre | University College of London | Closed out | 60 Months | |
| 65. | 0067 | Efficacy and Safety of Artemether-Lumefantrine, Artesunate-Amodiaquine and Dihydroartemisinin-Piperaquine for The Treatment of Uncomplicated Plasmodium Falciparum Malaria in Uganda. | 7/4/2018 | Dr. Adoke Yeka | Infectious Diseases Research Collaboration | National Malaria Consortium Program, MOH, WHO Country office | Ongoing | 21 Months | |
| 66. | 0068 | “GwokO Adunu pa Lutino” (GOAL Trial) – Determining the Impact of Penicillin on Latent Rheumatic Heart Disease: A Randomized Controlled Trial | 8/20/2018 | Dr. Emmy Okello | Uganda Heart Institute | Children’s National Medical Centre | Closed Out | 36 Months | |
| 67. | 0069 | Encochleated Oral Amphotericin for Cryptococcal Meningitis. (EnACT) | 10/4/2018 | Dr. David B. Meya | Infectious Diseases Institute | Matinaas Biopharma Nanotechnologies, Inc USA | Closed out | 24 Months | |
| 68. | 0070 | A Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of an Ebola Sudan Chimpanzee Adenovirus Vector Vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), in Healthy Adults. | 11/26/2018 | Dr. Betty Mwesigwa | Makerere University Walter Reed Project (MUWRP) | National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Health (NIH), Vaccine Research Centre (VRC) Bethesda, Maryland | Ongoing | 24 Months | |
| 69. | 0071 | Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS) | 8/23/2018 | Assoc Prof. Robert Opoka | Department of Pediatrics and Child Health, MUCHS | Thrasher Research Fund | Ongoing | 12 Months | |
| 70. | 0072 | An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSV∆G-ZEBOV-GP. | 9/21/2018 | Assoc Prof. Juliet Mwanga Amumpaire | Epicenter Mbarara Research Center | Medicins Sans Frontieres (MSF) | Ongoing | Undetermined | |
| 71. | 0073 | A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola vaccines Ad26.ZEBOV and/or MVA-BN-Filo, Phase 3. | 11/2/2018 | Dr. Hannah Kibuuka | Makerere University Walter Reed Project | Janssen Vaccines and Prevention B.V | Closed Out | 60 Months | |
| 72. | 0074 | A Randomized, Placebo-controlled Trial of HPV vaccination to reduce Cervical High-Grade Squamous Intraepithelial Lesions among HIV-infected Women Participating in an HPV Test-and-Treat Program. (CONVENANT) | 12/10/2018 | Dr. Jackson Orem | Uganda Cancer Institute | National Cancer Institute, Office of HIV and AIDS Malignancy | TBC | 60 Months | |
| 73. | 0075 | Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old in Uganda. | 10/12/2018 | Dr. Irene Lubega | Infectious Diseases Institute | Centre For Disease Control and Prevention | Ongoing | 36 Months | |
| 74. | 0076 | A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavarin-free HCV Therapy to HCV Infected Populations who are HCV Treatment Naïve with Evidence of Active HCV Infection. (The MINMON study) | 11/26/2018 | Dr. Cissy Kityo | Joint Clinical Research Centre | National Institute of Allergy and Infectious Diseases (NIAID) | Closed Out | 30 Months | |
| 75. | 0077 | An Open-label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4 Month Treatment of Bedaquiline plus Pretomanid plus Moxifloxacin plus Pyrazinamide (BPaMZ) Compared to a 6 Month Treatment of HRZE/HR (Control) in Adult Participants with Drug- Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants with Drug-Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB) | 12/4/2018 | Prof. Harriet Mayanja Kizza | Case Western Reserve University Research Collaboration (CWRU) | Global Alliance for TB Drug Development | Closed Out | 36 Months | |
| 76. | 0078 | A Phase 2, Open-label, Multicenter, Single arm study to evaluate the Pharmacokinetics, Safety, Tolerability and Anti-Mycobacterial activity of TCM207 in combination with a Background regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for the treatment of children and adolescents 0 months to <18 years of age who have Confirmed or Probable Pulmonary MDR-TB Protocol TMC207-C211 | 9/12/2019 | Dr. Rebecca Nantanda | MUCHS, Makerere University Lung Institute | Janssen Pharmaceuticals | Terminated | 60 Months | |
| 77. | 0079 | A Randomized, Double-Blind, Parallel-Group, Multicenter, Phase III Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Pediatric Patients with Sickle Cell Disease. (HESTIA3) | 1/23/2019 | Assoc Prof. Victor Musiime | Joint Clinical Research Centre | Astra Zeneca AB, Sweden | Terminated | 24 Months | |
| 78. | 0080 | Pharmacokinetic and Pharmacodynamic Evaluation of Etonogesterol Dose Escalation with Efavirenz based Antiretroviral Therapy in HIV-infected Ugandan Women. (PK-20) | 1/7/2019 | Prof. Mohammed Lamorde | Infectious Diseases institute | University of Pittsburgh | Ongoing | 36 Months | |
| 79. | 0081 | Compassionate healthcare and frontline workers and ring vaccination project intended to evaluate safety of the Ebola vaccine in Uganda. Version 1 Expanded Access-Uganda | 11/26/2018 | Dr. Bernard Opar | Ministry of Health Uganda supported by the World Health Organization | World Health Organization | Terminated | ||
| 80. | 0084 | IMPAACT 2009: Pharmacokinetics, Feasibility, Acceptability and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants. | 11/26/2018 | Dr. Nicolette Nabukeera Barungi | Baylor College of Medicine Children’s Foundation | National Institute of Allergy and Infectious Diseases (NIAID) | Ongoing | 36 Months | |
| 81. | 0086 | “Randomized trial to compare Magnesium Sulphate administration for preeclampsia and eclampsia: Springfusor versus standard approach | 1/18/2019 | Dr. Sam Ononge | Department of Obstetrics and Gynecology, Makerere University College of Health Sciences | Makerere University College of Health Sciences | Closed Out | 24 Months | |
| 82. | 0087 | A Randomized, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease. (HESTIA3) | 1/30/2019 | Dr. Kibuuka Afizi | Infectious Diseases Research Collaboration | Astra Zeneca | Not Initiated | 24 Months | |
| 83. | 0088 | Effect of preoperative bicarbonate on Maternal and Perinatal outcomes of obstructed labor; A Study Protocol for a Randomized Controlled Trial | 1/23/2019 | Dr. Milton Musaba Wamboko | Department of Obstetrics and Gynecology, Makerere University College of Health Sciences | Survival Pluss Project NORA/NORHED Program | Closed Out | 12 Months | |
| 84. | 0089 | A Randomized, Four-arm Open-Label Phase IIb Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected patients on Efavirenz-or Dolutegravir based Antiretroviral Therapy. (SAEFRIF) | 3/15/2019 | Dr. Christine Sekaggya | Infectious Diseases Institute,Makerere University College of Health Sciences | Infectious Diseases Institute | Ongoing | ||
| 85. | 0090 | A Phase I/II, Open-Label, Randomized Crossover Pharmacokinetic, Safety and Acceptability Study of the Abacavir/Lamivudine/Lopinavir/Ritonavir/ - 30/15/40/10mg (4-in-1) Fixed Dose Combination vs Lopinavir/Ritonavir - 40/10mg pellets plus Dual Abacavir/Lamivudine - 60/30mg Tablets in HIV Infected Children. | 1/20/2019 | Assoc Prof. Victor Musiime | Joint Clinical Research Centre | Drugs for Neglected Diseases Initiative (DNDI) Switzerland | Early Termination by the Sponsor | 12 Months | |
| 86. | 0091 | Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia. (ACACIA) | 4/23/2019 | Assoc Prof. David Meya | Infectious Diseases Institute | Infectious Diseases Institute | Ongoing | 60 Months | |
| 87. | 0092 | Optimizing benefits while reducing risks of iron in malaria-endemic areas: The OptiM | 3/15/2019 | Dr. Ezekiel Mupere | Department of Pediatrics and Child health | University of Minnesota | Ongoing | ||
| 88. | 0093 | Population Difference in Vaccine Response: The Role, Reversibility and Mediators of Immunomodulation by Chronic Infections in the Tropics (POPVAC).” – Protocol A: The Effect of Intensive Treatment for Schistosomiasis on Response to Vaccines among Island Adolescents. | 5/28/2019 | Prof. Alison Elliot | MRC-UVRI and LSHTM | Medical Research Council | Ongoing | 48 Months | |
| 89. | 0094 | Population Difference in Vaccine Response: The Role, Reversibility and Mediators of Immunomodulation by Chronic Infections in the Tropics (POPVAC).” – Protocol C: The Impact of BCG ‘Pre-Immunization’ on the Response to Vaccines among Ugandan Adolescents Participating in the Entebbe Mother and Baby Study. | 5/28/2019 | Prof. Alison Elliot | MRC-UVRI and LSHTM | London School of Hygiene and Tropical Medicine | Ongoing | 36 Months | |
| 90. | 0095 | A Randomized, Open-label, Parallel-group, Single Dose Regimen, Phase 2a Study to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 Dose Levels of Artefenomel (OZ439) Given in Combination with Ferroquine (FQ) and FQ Alone, in African Patients with Uncomplicated Plasmodium Falciparum Malaria. | 5/2/2019 | Dr. Adoke Yeka | Infectious Diseases Research Collaboration | Sanofi-Aventis Recherche and Development; Medicines Malaria Venture (MMV) | Closed Out | 24 Months | |
| 91. | 0096 | Trial of Faropenem and Cefadroxil (in Combination with Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients with Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers. | 5/16/2019 | Dr. Cissy Kityo | Joint Clinical Research Centre | National University Hospital, 5 lower Kent Ridge Rd Singapore | Closed out | 3-4 Months | |
| 92. | 0098 | Randomized Trial to Evaluate Mirasol Whole Blood Pathogen Reduction Technology System to Reduce Malaria and Other Transfusion Transmitted Infections (Uganda Mirasol Trial). | 7/4/2019 | Dr. Irene Lubega | MU-JHU | Department of Defence, Congressionally Directed Medical Research Programme | Ongoing | 42 Months | |
| 93. | 0099 | Pharmacokinetics ad Pharmacodynamics of Azithromycin in Severe Malaria Bacterial Co-infection in African Children: TABS PKPD Study | 11/25/2019 | Prof. Peter Olupot-Olupot | Mbale Clinical Research Institute (MCRI) | Imperial College London. AIMI Vanden Oeven | Ongoing | 18 Months | |
| 94. | 0100 | Monitored Emergency Use of Unregistered and Experimental Drugs (MEURI): Favipiravir for Exposed Staff to Filovirus (Marbug and Ebola) in Uganda | 6/18/2019 | Assoc Prof. Juliet Mwanga Amumpaire | MSF Epicenter Mbarara | Medicines Sans Frontieres | Ongoing | Undetermined | |
| 95. | 0101 | Nucleosides and Darunavir/Dolutegravir in Africa (The NADIA Trial): A Randomised Controlled Trial of Darunavir versus Dolutegravir and Tenofovir versus Zidovudine in Second-line Antiretroviral Therapy Regimens for the Public Health Approach in Sub-Saharan Africa | 6/11/2019 | Dr. Andrew Kambugu | Infectious Diseases Institute | Infectious Diseases Institute | Closed out | 36 Months | |
| 96. | 0102 | A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined with Local Standard of Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as a Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Children, Adolescents and Adults in Uganda | 4/7/2019 | Dr. Henry Ddungu | Uganda Cancer Institute (UCI) | Fred Hutchinson Cancer Research Centre | Ongoing | 48 Months | |
| 97. | 0103 | A Randomized, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagleror versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease | 6/11/2019 | Dr. Sylvia Kusemererwa | MRC/UVRI and LSHTM | Astra Zeneca AB | Terminated | 24 Months | |
| 98. | 0104 | A Phase I/II Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® with or without AP 10-701 for Intestinal Schistosomiasis in Healthy Ugandan Adults. | 8/28/2019 | Dr. Hannah Kibuuka | MUWRP | Baylor College of Medicine | Ongoing | 36 Months | |
| 99. | 0105 | Monitored Emergency Use for Ebola Virus Disease | 6/18/2019 | Dr. Francis Kiweewa | MUWRP | Joint Mobile Emerging Disease Intervention Clinical Capability (JMEDICC) program | Not Initiated | 36 Months | |
| 100. | 0106 | An open-label, single arm study to provide additional information on immunogenicity and safety of Ad26.ZEBOV/MVA-BN-Filo | 6/19/2019 | Prof. Pontiano Kaleebu | MRC/UVRI and LSHTM | London School of Hygiene and Tropical Medicine LSHTM | Ongoing | Undetermined | |
| 101. | 0107 | Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis (TRUNCATE-TB). | 8/16/2019 | Dr. Christine Sekaggya-Wiltshire | Infectious Diseases Institute | University College London. | Closed out | 36 Months | |
| 102. | 0108 | Remdesivir (GS-5734): Monitored Emergency Use for Ebola Virus Disease. | 6/18/2019 | Dr. Bernard Opar | Ministry of Health | Medicines Sans Frontieres (MSF) | Not Initiated | Undetermined | |
| 103. | 0109 | REGN3470-3471-3479: Monitored Emergency Use for Ebola virus Disease. | 6/18/2019 | Dr. Bernard Opar | Ministry of Health | Medicines Sans Frontieres (MSF) | Not Initiated | Undetermined | |
| 104. | 0110 | ZMapp: Monitored Emergency Use for Ebola Virus Disease. Version 1.0 dated 16 December 2018. (ZMAPP) | 6/18/2019 | Dr. Bernard Opar | Ministry of Health | Medicines Sans Frontieres (MSF) | Not Initiated | Undetermined | |
| 105. | 0111 | A Phase IV Open-Label Trial to Assess Bone Mineral Density in a Cohort of African Women on Depo-provera and Tenofovir Disoproxil Fumarate Switched to Tenofovir Alafenamide Fumarate based Anti-Retroviral Therapy. (BONE STAR) | 9/4/2019 | Dr. Flavia Matovu Kiweewa | MU-JHU Research Collaboration | Gilead Sciences | Ongoing | 36 Months | |
| 106. | 0112 | Combined HIV Adolescent PrEP and Prevention: On Demand Pre-Exposure Prophylaxis to Provide Protection from HIV in Men using Foreskin Tissue to Estimate Protection (CHAPS II) | 9/19/2019 | Prof. Pontiano Kaleebu | MRC/UVRI and LSHTM Uganda Research Institute | Perinatal HIV Research Unit, Chris Hani Bagwaranth Academic Hospital, University of Witswater Rand University | Closed-out | 12 Months | |
| 107. | 0113 | Non-Inferiority Fractional-Doses Trial for Yellow Fever Vaccine. (NIFTY) | 9/23/2019 | Dr. Maria Louise Namulwana | Epicentre Mbarara Research Centre | University of Oxford UK. KEMRI-Welcome Trust Research Programme | Ongoing | 36 Months | |
| 108. | 0114 | Efficacy and Safety of fexinidazole in patients with Human African Trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense: a multicenter, open-label clinical trial | 12/27/2019 | Prof. Enock Matovu | Makerere University, College of Veterinary Medicine, Animal Resources and Biosecurity | Drugs for Neglected Diseases Initiative (DNDI) | Closed out | 39 Months | |
| 109. | 0115 | A5300B/12003B/PHOENIx: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIX MDR-TB) | 9/27/2019 | Dr. Henry Mugerwa | Joint Clinical Research Centre | Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), Department of Health and Human Services (DHHS) | Ongoing | 60 Months | |
| 110. | 0116 | A5300B/12003B/PHOENIx: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIX MDR-TB), | 10/21/2019 | Dr. Eric Wobudeya | MU-JHU | National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD) | Ongoing | 60 Months | |
| 111. | 0117 | Population differences in vaccine response: the role, reversibility and mediators of immunomodulation by chronic infections in the tropics (POPVAC). – Protocol B: The effect of intermittent preventive treatment for Malaria with dihydroartemisinin –piperaquine on response to vaccines among rural adolescents. (POPVAC-B) | 9/11/2019 | Prof. Alison Elliott | MRC-UVRI and LSHTM | London School of Hygiene and Tropical Medicine (LSHTM) | Ongoing | 48 Months | |
| 112. | 0118 | High Dose Oral Rifampicin to Improve Survival from Adult Tuberculosis Meningitis: A Double-blinded Randomised Controlled Phase III Trial. (HARVEST) | 12/23/2019 | Assoc Prof. David Meya | Infectious Diseases Institute | Infectious Diseases Institute (IDI) | On-going | 60 Months | |
| 113. | 0119 | Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: A multicenter open label randomized controlled clinical trial (EMPIRICAL) | 3/11/2020 | Assoc Prof. Victor Musiime | MUCHS | Servicia Madrileno de Salud (SERMAS)-Fundacion para la Investigacion Biomedica | Ongoing | 36 Months | |
| 114. | 0120 | Birth Asphyxia in Uganda: Prevalence, Associated Factors and Effect of Intra-Partum Oxygen Administration on Fetal and Early Neonatal Outcomes. (INTRA-O) | 12/11/2019 | Ms. Elizabeth Ayebare | Department of Nursing, School of Health Sciences, Makerere University. | Ayebare Elizabeth | Closed Out | 8 Months | |
| 115. | 0121 | Phase 3b, Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy. (DELIVER) | 12/6/2019 | Dr. Clemensia Nakabitto | MU-JHU | Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH) | Ongoing | 36 Months | |
| 116. | 0122 | Impact of Increased Praziquantel Frequency On Childhood Fibrosis in Persistent Schistosmiasis Morbidity Hot Spots (FibroScHot) | 1/23/2020 | Dr. Edridah Tukahebwa | Vector Control Division | Cambridge University Hospitals NHS Foundation Trust, The Chancellor, Masters and Scholars of the University of Cambridge | Closed out | 32 Months | |
| 117. | 0124 | Safety and efficacy of Dolutegravir and EFV400 for pregnant and breastfeeding women: a randomised non-inferiority clinical trial. | 5/8/2020 | Prof. Jackson Mukonzo | Department of Pharmacology and Therapeutics, MAKCHS | Hawassa University, Ethiopia | Ongoing | ||
| 118. | 0125 | A phase IIb three-arm, two-stage HIV-1 prophylactic vaccine trial with a second randomisation to compare TAF/FTC in comparison to TDF/FTC as pre-exposure prophylaxis (PrEPVacc) | 3/26/2020 | Prof. Pontiano Kaleebu | MRC/UVRI | Jonathan Weber, Imperial College, Room 2.15, 2 Floor, Faculty Building, South Kesington campus, Exhibition road, London | Closed out | 36 Months | |
| 119. | 0126 | A Phase 3, Open-label, Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir administered with Rifampicin to HIV Positive Adults on Second-line ART Regimen with Suppressed HIV-1 Viral Load (DERIVE). | 5/22/2020 | Dr. Henry Mugerwa | Joint Clinical Research Centre | University of Liverpool | Ongoing | 18 Months | |
| 120. | 0128 | DPART Study Dihydroatemisinin in the context of Antiretroviral Therapy. (DPART) | 7/30/2020 | Dr. Grace Paul Kisitu | Baylor College of Medicine , Children’s Foundation | National Institute of Child Health and Human Development (NICHD) | Ongoing | ||
| 121. | 0128 | A multicenter, phase III double blind, randomized active controlled study to evaluate the efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in newborn infants. (VPM) | 7/8/2020 | Dr. Victoria Nankabirwa | Makerere University School of Public Health | Serum Institute of India, Private Limited | Terminated | 36 Months | |
| 122. | 0128 | Phase 3B, Randomized, Open-label, Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in breastfeeding Mother-infant Pairs. Protocol Version 1.0 dated 24 July 2019. (TRUVADA) | 5/3/2020 | Dr. Brenda Gati Mirembe | MU-JHU | Division of AIDS (DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID) | Closed-out | 24 Months | |
| 123. | 0131 | ROSuvastatin Evaluation as a Tuberculosis Treatment Adjunct (ROSETTA) | 7/20/2020 | Dr. Cissy Kityo Mutuluuza | Joint Clinical Research Centre | National University Hospital | Closed out | 11 Months | |
| 124. | 0132 | Impact of oral step-down to amoxicillin or co-amoxiclav and of duration of antibiotic therapy on effectiveness, safety and selection of antibiotic resistance in severe childhood community-acquired pneumonia (CAP): a randomized controlled trial. (PediCAP) | 6/15/2020 | Assoc Prof. Victor Musiime | Department of Pediatrics and Child Health | Fondazione PENTA ONLUS | Ongoing | 24 Months | |
| 125. | 0133 | Praziquantel for children under age four years: A phase II PK/PD driven dose finding trial (PIP) | 7/27/2020 | Dr. Patrice Mawa | MRC/UVRI AND LSHTM | Rhode Island Hospital, Center for International Health Research | Ongoing | 36 Months | |
| 126. | 0134 | Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CABLA) for Prevention of HIV among Female Adolescents-A Sub-study of HPTN084. (CABLA) | 6/26/2020 | Dr. Brenda Gati Mirembe | MU-JHU | Division of AIDS (DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), US National Institute of Health (NIH | Ongoing | 24 Months | |
| 127. | 0135 | Optimal chemopreventive regimens to prevent malaria and improve birth in Uganda, | 7/30/2020 | Prof. Moses Kamya | IDRC | The National Institute of Child Health and Human Development (NICHD) | Closed out | 60 Months | |
| 128. | 0136 | Pharmacokinetics and tolerability of Adjunctive Linezolid for the Treatment of andomized meningitis (ALTER): a Phase II trial, open-label, randomized trial (ATLER) | 9/11/2020 | Dr. Freddie Mukasa Kibengo | MRC/UVRI & London School of Hygiene and Tropical Medicine | University of California, San Francisco | Closed Out | 24 Months | |
| 129. | 0137 | Comparison of Mortality and Frequency of Red Blood Cell Allo-immunization in recipients of Leuko-reduced and Non-Leuko-reduced Blood Transfusion in Uganda. | 9/22/2020 | Dr. Clement Dove Okello | Uganda Cancer Institute | Uganda Cancer Institute (UCI) | Closed out | 36 Months | |
| 130. | 0138 | Randomized controlled non-inferiority trial of topical chlorhexidine 0.2% versus topical natamycin 5% for fungal keratitis in East Africa | 9/30/2020 | Dr. Simon Arunga | Mbarara University and Referral Eye Center | London School of Hygiene and Tropical Medicine (LSHTM) | Ongoing | 36 Months | |
| 131. | 0139 | The safety and andomizedy of a combined Pertussis-cOntaining vaccine (Tdap) for HIV-infected pregnant WomEn and their newboRns-A Randomized Clinical Trial (andomized) | 9/23/2020 | Dr. Eva Nakabembe | Makerere University College of Health Sciences | St. Georges University of London, Joint Research and Enterprise Services | Ongoing | 24 Months | |
| 132. | 0140 | An open-label, andomized, andomized, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19 | 12/27/2021 | Assoc Prof Juliet Mwanga-Amumpaire | Epicentre Mbarara Research Centre | Dr. Rebecca F. Grais | Ongoing | 12 Months | |
| 133. | 0141 | A randomized trial of 6 months intensified anti-tuberculosis and 2 months anti-inflammatory treatment for HIV-infected and HIV-uninfected African and Asian children with tuberculosis meningitis. (SURE STUDY) | 10/29/2020 | Dr. Eric Wobudeya | MU-JHU | University College of London | Ongoing | 36 Months | |
| 134. | 0142 | Optimizing DPT-containing vaccine infant immunization schedules in UGANDA. (OPTIMMS) | 2/4/2021 | Prof. Alison Elliot | MRC/UVRI | University of Oxford | Ongoing | 48 Months | |
| 135. | 0143 | The Efficacy and Safety of hydroxychloroquine for the treatment of non-severe covid-19 in adults in Uganda. A randomized open label phase II clinical trial (HONEST) | 9/9/2020 | Dr. Pauline Byakika-Kibwika | Makerere University College of Health Sciences | Makerere University | Terminated | 24 Months | |
| 136. | 0144 | Effectives of low-dose Theophylline for the management of Biomass-associated COPD. | 12/10/2020 | Dr. Bruce Kirenga | Makerere University Lung Institute (MLI) | National Institute of Health | Ongoing | 24 Months | |
| 137. | 0145 | Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals by addressing Artemether-Lumefantrine and Efavirenz, A randomized Controlled Trial (OPTIMAL) | 3/11/2020 | Prof. Pauline Byakika-Kibwika | Makerere University College of Health Sciences (MUCHS) | Infectious Diseases Institute | Ongoing | 36 Months | |
| 138. | 0146 | Assessment of safety and efficacy of COVID-19 Convalescent Plasma for treatment of COVID-19 in adults in Uganda; A phase III randomized controlled trial. (CCP) | 9/14/2020 | Assoc Prof. Bruce Kirenga | Makerere University Lung Institute (MLI) | Makerere University | Ongoing | 5 Months | |
| 139. | 0147 | Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda: A single Arm Open Label Trial. (BRAIN SAFE II) | 12/2/2020 | Assoc Prof. Richard Idro | Makerere University College of Health Sciences (MUCHS) | Global Health Uganda, Limited | Ongoing | 36 Months | |
| 140. | 0148 | Pilot feasibility study for uptake and implementation of a clinical algorithm for warfarin dosing in sub-saharan African patients in the War-PATH Ugandan and South African Clinical study sites. | 1/8/2021 | Dr. Catriona Waitt | IDI | University of Liverpool | Ongoing | 18 Months | |
| 141. | 0149 | Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children with Sickle Cell Anemia in Eastern and Southern Africa. (CHEMCHA) | 11/19/2020 | Assoc Prof. Richard Idro | MUCHS | Liverpool School of Tropical Medicine, UK | Ongoing | 60 Months | |
| 142. | 0150 | A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease. | 2/24/2021 | Dr. Henry Ddungu | UCI | IMARA, Inc C/O Eleanor Lisbon,MD,MPH Vice President, Clinical Development, IMARA | Early termination | 36 Months | |
| 143. | 0151 | A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease. | 2/24/2021 | Dr. Abner Tagoola | Jinja Regional Referral Hospital, Sickle Cell Clinic | IMARA, Inc C/O Eleanor Lisbon,MD,MPH Vice President, Clinical Development, IMARA | Early termination | 36 Months | |
| 144. | 0152 | A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease | 2/24/2021 | Assoc Prof. Victor Musiime | JCRC | IMARA, Inc C/O Eleanor Lisbon,MD,MPH Vice President, Clinical Development, IMARA | Early termination | 36 Months | |
| 145. | 0153 | A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease | 2/24/2021 | Dr. Afizi Kibuuka | IDRC | IMARA, Inc C/O Eleanor Lisbon, MD, MPH Vice President, Clinical Development, IMARA | Early termination | 36 Months | |
| 146. | 0154 | A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease | 2/24/2021 | Prof. Grace Ndeezi | Makerere College of Health Sciences/ Mulago Hospital | IMARA, Inc C/O Eleanor Lisbon, MD, MPH Vice President, Clinical Development, IMARA | Early termination | 36 Months | |
| 147. | 0155 | An Open-Label, Roll-over study with Rilpivirine in Combination with a Background Regimen Containing Other Antiretrovirals (ARVs) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Who Participated in Rilpivirine Pediatric Studies | 2/10/2021 | Dr. Francis Ssali | JCRC | JANSSEN Pharmaceuticals (Pty) Ltd | Ongoing | 48 Months | |
| 148. | 0156 | Multicenter, Adaptive, Randomized, Blinded Controlled Trial of safety and Efficacy of investigational Therapeutics for hospitalized patients with COVID-19 | 1/20/2021 | Dr. Joseph Lutaakome | MRC/UVRI and LSHTM | University of Minnesota | Ongoing | 36 Months | |
| 149. | 0157 | Effect of Vitamin D supplementation on sickle cell disease hospitalization and related complications among children in Mulago Hospital: A randomized clinical trial | 2/22/2021 | Prof. Grace Ndeezi | Department of Pediatrics and Child Health | Makerere Research Innovation Fund (Mak RIF) | Ongoing | 12 Months | |
| 150. | 0158 | Safety and Pharmacokinetics of the combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults | 2/17/2021 | Dr. Andrew Mujugira | IDI | International AIDS Vaccine Initiative | Ongoing | 36 Months | |
| 151. | 0159 | An Open-label, randomized, Single intravenous dosing to investigate the effect of fixed dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers. (REMTLAR) | 2/12/2021 | Prof. Mohammed Lamorde | IDI | Infectious Diseases Institute | Ongoing | 12 Months | |
| 152. | 0160 | Intensified tuberculosis treatment to reduce the mortality of HIV-Infected and HIV-uninfected patients with tuberculosis meningitis: a Phase III Randomized Controlled Trial. (INTENSE-TBM) | 4/8/2021 | Dr. Conrad K Muzoora | Mbarara University of Science and Technology (MUST) | Prof. Francois Dabis | Ongoing | 48 Months | |
| 153. | 0161 | A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-Infected, Virological Suppressed Adults in Sub-Saharan Africa. (CARES) | 3/3/2021 | Dr. Cissy Kityo | Joint Clinical Research Centre | Joint Clinical Research Centre | Ongoing | 39 Months | |
| 154. | 0162 | The effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination | 8/18/2021 | Dr Cissy Kityo Mutuluuza | Joint Clinical Research Centre | University of Minnesota | Ongoing | 60 Months | |
| 155. | 0163 | A clinical Evaluation of Efficacy, Safety, Immunogenicity and Tolerability of UBV-10N, A Natural Product in Adult Patients Infected with Sar-Cov-2 (Covid-19), In Uganda. (UBV-10N) | 1/25/2021 | Dr. Grace Nambatya Kyeyune | Director, Natural Chemotherapeutics Research Institute | PRESIDE (Presidential Scientific Initiative on Epidemics) | Ongoing | 12 Months | |
| 156. | 0164 | Safety and Pharmacokinetics of the combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults. (C100) | 3/24/2021 | Dr. Brenda Okech | Uganda Virus Research Institute/ International AIDS Vaccine Initiative (UVRI/IAVI) | International AIDS Vaccine Initiative (IAVI) | Ongoing | 36 Months | |
| 157. | 0165 | Pancreatic Enzymes and Bile Acids: A non-antibiotic approach to Treat Intestinal Dysbiosis in Acutely III Severely Malnourished Children. (PB SAM) | 9/15/2021 | Dr. Ezekiel Mupere | CWRU | University of Oxford | Closed out | 36 Months | |
| 158. | 0166 | Paracetamol for Acute Renal Injury in Severe Malaria Trial (PARIST) | 8/24/2021 | Prof. Peter Olupot Olupot | Mbale Clinical Research Institute (MCRI) | Mbale Clinical Research Institute | Ongoing | 24 Months | |
| 159. | 0167 | Identification, Validation & Optimization of available drug molecules for clinical treatment of COVID-19. (IVCOM) | 3/4/2021 | Prof. Jackson Mukonzo | Department of Pharmacology &Therapeutics | Presidential Scientific Initiative on Epidemics | Ongoing | 12 Months | |
| 160. | 0168 | A randomized Trial to investigate strategies to reduce mortality among HIV-Infected and HIV-exposed children admitted with severe acute malnutrition in Mulago Hospital, Kampala, Uganda. (REDMOTHIV) | 5/4/2021 | Assoc Prof. Victor Musiime | Makerere University College of Health Sciences | Makerere University Research and Innovations Fund | Ongoing | 36 Months | |
| 161. | 0169 | A Phase II trial to describe the pharmacokinetics, safety and efficacy of pharmacogenetics-guided dosing of isoniazid in patients with HIV-associated TB (PHINX) | 9/13/2021 | Dr. Christine Sekaggya-Wiltshire | IDI | Makerere University | Ongoing | 24 Months | |
| 162. | 0170 | Evaluation of pharmacokinetics, safety and feasibility for administration of two doses of intravenous ascorbic acid combined with vitamin B1 for the management of adult patients admitted with sepsis to Kiruddu National Referral Hospital. (REVISTA) | 6/8/2021 | Dr. Shevin Jacob | Infectious Diseases Institute | Liverpool School of Tropical Medicine | Ongoing | 12 Weeks | |
| 163. | 0171 | A Phase 1 Trial of ChADOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern African. (HIV-CORE 006) | 6/4/2021 | Prof. Pontiano Kaleebu | MRC/UVRI | University of Oxford | Ongoing | 21 Months | |
| 164. | 0172 | Gastroenteritis and Rehydration of children with Severe Acute Malnutrition (GASTROSAM) | 11/25/2021 | Prof. Peter Olupot-Olupot | MCRI | Imperial College London | Ongoing | 24 Months | |
| 165. | 0173 | Implementation of a bundle of care to improve anticoagulation control in patients receiving warfarin in Uganda and South Africa. (WARFARIN BUNDLE) | 7/19/2021 | Dr. Catriona Waitt | IDI | University of Liverpool | Ongoing | 36 Months | |
| 166. | 0174 | A multi-Centre, andomized, placebo controlled, double-blind, parallel group study to evaluate the safety, tolerability and immunogenicity of two doses of Group B Streptococcus vaccine (GBS-NN/NN2) in women who are pregnant and living with HIV and women who are pregnant and do not have HIV. (MINERVAX) | 7/9/2021 | Dr. Musa Sekikubo | MU-JHU | MinervaX A/S | Ongoing | 18 Months | |
| 167. | 0175 | Finding Solutions to thrive after birth asphyxia in Africa: An open-label dose-finding clinical trial (Phase Ib study). SANE-Uganda. | 8/31/2021 | Dr. Nathan Kenya -Mugisha | WALIMU | Research Institute of the McGill University Health Centre | Ongoing | 18 Months | |
| 168. | 0176 | A5372 Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals. (A5372) | 7/16/2021 | Dr. Cissy Kityo | JCRC | National Institute of Allergy and Infectious Diseases | Closed out | 12 Months | |
| 169. | 0177 | A parallel-group, Phase III, multi-stage. Modified double-blind, multi-armed study to assess the efficacy, safety and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older. (VAT0008) | 8/11/2021 | Dr. Hannah Kibuuka | MUWRP | Sanofi Pasteur, Inc | Ongoing | 24 Months | |
| 170. | 0178 | An Open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose In Human Immunogenicity Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen. (EBOVAC BOOST) | 8/25/2021 | Prof. Pontiano Kaleebu | MRC/UVRI/LSHTM | London School of Hygiene and Tropical Medicine (LSHTM) | Ongoing | 6 Months | |
| 171. | 0179 | B-ENHANCEMENT of HBV Vaccination in Persons Living With HIV (Bee-HIVe): Evaluation of HEPLISAV-B. | 10/8/2021 | Dr. Francis Ssali | JCRC | National Institute of Allergy and Infectious Diseases (NIAID) | Ongoing | 30 Months | |
| 172. | 0180 | A randomized clinical Trial of Early Empiric Anti-Mycobacterium tuberculosis therapy for Sepsis in Sub-Saharan Africa (ATLAS trial) | 9/27/2021 | Dr. Conrad K. Muzoora | Mbarara University of Science and Technology (MUST), Mbarara Regional Referral Hospital | National Institute of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Division of Microbiology and Infectious Diseases (DMID) | Ongoing | 36 Months | |
| 173. | 0181 | Efficacy and safety of artemether-lumefantrine, pyronaridine- Artesunate, Artesunate-amodiaquine and dihydroartemisinin-piperaquine for the treatment of uncomplicated plasmodium falciparum malaria in children in Uganda | 11/9/2021 | Dr. Adoke Yeka | IDRC | United States of Agency for International Development (USAID) | Ongoing | 24 Months | |
| 174. | 0182 | A phase 1 Study to determine the safety and Immunogenicity of candidate Rift Valley Fever virus (RVFV) vaccine ChAdox1 among healthy adult volunteers in Uganda | 11/9/2021 | Dr. Irene Andia Biraro | Makerere University College of Health Sciences | National Institute of Medical Research-Mbeya Medical Research Centre | Ongoing | 48 Months | |
| 175. | 0183 | A Phase I study to determine the safety and immunogenicity of the candidate Rift Valley Fever Virus (RVFV) vaccine ChAdOx1 RVF among healthy adult volunteers in Uganda (RVF002) | 9/29/2021 | Prof. Pontiano Kaleebu | MRC/UVRI LSHTM Uganda Research Unit, Masaka site. | Dr. Stephen Conway | Ongoing | 12 weeks from date of enrollment of the last volunteer (s) | |
| 176. | 0184 | Phase I/II study of the Safety, Acceptability. Tolerability and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents. (IMPAACT 2017) | 11/12/2021 | Dr. Violet Korutaro | Baylor College of Medicine Children’s Foundation | National Institute of Allergy and Infectious Disease Institute (NIAID) and Eunice Kennedy Shriver, National Institute of Child Health and Human Development (NICHD). National Institute of Mental Health (NIMH) | Ongoing | 84 Months | |
| 177. | 0185 | DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children with HIV Infection Aged 2 to <15 Years Old (D3: PENTA 21) | 10/7/2021 | Dr. Cissy Kityo | Joint Clinical Research Centre | Fondazione PENTA ONLUS | Ongoing | 60 Months (5 years) | |
| 178. | 0186 | A clinical trial to assess the safety and immunogenicity of a modified self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19, in SARS-CoV-2 seronegative and seropositive Ugandan population (COVAC) | 9/14/2021 | Prof. Pontiano Kaleebu | MRC/UVRI LSHTM Uganda Research Unit | Imperial College London | Ongoing | 10 Months | |
| 179. | 0187 | Drug Interactions between Dolutegravir (DTG) and escalating-doses of Rifampicin (RIF) Study (DORIS Study) | 12/13/2021 | Prof. Mohammed Lamorde | Infectious Diseases Institute | University of Liverpool | Ongoing | 24 Months | |
| 180. | 0189 | An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyper immune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19. (OTAC) | 11/17/2021 | Dr. Joseph Lutaakome | MRC/UVRI LSHTM Uganda Research Unit | University of Minnesota | Ongoing | 36 Months | |
| 181. | 0190 | Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccines in Regions with SARS-CoV-2 Variants of Concern. (CoVPN 3008) | 9/16/2021 | Dr. Cissy Kityo | Joint Clinical Research Centre | South African Medical Research Council (SAMRC) | Ongoing | 14 Months | |
| 182. | 0191 | Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccines in Regions with SARS-CoV-2 Variants of Concern. (CoVPN 3008) | 9/20/2021 | Dr. Deo Wabwire | MU-JHU | South African Medical Research Council (SAMRC) | Ongoing | 14 Months | |
| 183. | 0192 | Phase I/II study of the Safety, Acceptability. Tolerability and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents. (IMPAACT 2017) | 11/8/2021 | Dr. Maxensia Owor | MU-JHU | Division of AIDS (DAIDS) | Ongoing | 84 Months | |
| 184. | 0193 | Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern. (CoVPN 3008) | 9/16/2021 | Dr. Peter James Elyanu | BAYLOR | South African Medical Research Council (SAMRC) | Ongoing | 14 Months | |
| 185. | 0194 | Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern. (CoVPN 3008) | 9/17/2021 | Dr. Annet Nanvubya | UVRI/IAVI | South American Medical Research Council (SAMRC) | Ongoing | 14 Months | |
| 186. | 0195 | A phase 3, randomized, active-controlled, double-blind clinical study to evaluate the efficacy and safety of oral Islatravir once-monthly as pre-exposure prophylaxis in cisgender women at high risk for HIV-1 infection. (MK-8591-022/ IMPOWER-022) | 10/19/2021 | Dr. Brenda Gati Mirembe | MU-JHU | Merck Sharp & Dohme corp. a subsidiary of Merck & Co. Inc | Closed out | 48 Months | |
| 187. | 0196 | Enhancing Immunity to Malaria in Young Children with effective Chemoprevention (MIC-DROP) | 12/3/2021 | Prof. Moses Kamya | IDRC | National Institute of Child Health and Human Development | Ongoing | 60 Months | |
| 188. | 0197 | A Phase 2, Open-lbel, Single-arm Multicenter Study to evaluate the pharmacokinetics safety andomized and efficacy of andomize to RPV plus other ARVS in HIV infected children (Age 2 to < years) who are virologically suppressed (PICTURE) | 12/10/2021 | Dr. Francis Ssali | JCRC | Janssen Pharmaceuticals (PTY) Ltd | Ongoing | 54 Weeks | |
| 189. | 0200 | A Phase 3 Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis Adolescent Girls and Young Women at Risk of HIV Infection. (PURPOSE-1) | 12/1/2021 | Dr. Flavia Matovu Kiweewa | MU-JHU | Gilead Sciences. Inc | Ongoing | 72 Months | |
| 190. | 0201 | A randomized open-label 2-arm, 96-week trial evaluate the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-saharan Africa (Breather Plus) | 12/13/2021 | Dr. Adeodata R. Kekitiinwa | Baylor | University College of London (UCL), UK | Ongoing | 60 Months | |
| 191. | 0202 | Cross-sectional prevalence study of schistosomiasis and soil-transmitted helminthiasis with nested open-label andomized controlled study of evaluating the impact of fatty meal co-administration and double-dosing on albendazole effectiveness against hookworm infection among school-aged children in Mayuge district: Implications for Mayuge NTDs Elimination (MANE) Project | 1/24/2022 | Dr. Eun Seok Kim | LSHTM, World Vision | World Vision Uganda-Mayuge Neglected Tropical Diseases | Closed out | 2 Months | |
| 192. | 0203 | A Multicenter, prospective, randomized, placebo controlled, open label, stepped wedge clinical trial of respiratory support with continuous positive airway pressure or high flow Oxygen therapy in adults with acute hypoxemic respiratory distress in Sub-Saharan Africa. (ARISE) | 12/14/2021 | Dr Arthur Kwizera | Department of Anaesthesia and Critical Care Makerere University College of Health Sciences | Makerere University Research University | Ongoing | 15 Months | |
| 193. | 0204 | Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum | 1/17/2022 | Dr. Victoria Ndyanabangi | Baylor College of Medicine | National Institute of Allergy and Infectious Diseases (NIAID) | Ongoing | 60 Months | |
| 194. | 0205 | Safety and Efficacy of COVIDEX Therapy in management of covid-19 patients; a randomized controlled clinical trial | 1/27/2022 | Prof. Jackson Mukonzo | Makerere University, College of Health Sciences | The Government of Uganda (GOU) and Jena Herbal Limited | Ongoing | 12 Months | |
| 195. | 0206 | Determination of Adequate Tuberculosis Regimen in Adults and adolescents andomized with HIV-associated severe immune suppression. A Phase III controlled randomized clinical trial | 3/23/2022 | Dr. Conrad Muzoora | Epicentre Mbarara Research Centre/Mbarara University of Science and Technology | Inserm-ANRS French National Institute for Health and Medical Research (Inserm) ANRS Infectious Emergent Diseases- Autonomous Agency of Inserm (ANRS) | Ongoing | 60 Months | |
| 196. | 0208 | A Randomized, Observer-Blind, Phase 2 Clinical Trial of COVAC-2 in Generally Healthy Adults | 5/16/2022 | Prof. Pontiano Kaleebu | Medical Research Council/ Uganda Virus Research Institute (MRC/UVRI) | Vaccine and Infectious Disease Organization (VIDO) | Ongoing | 20 Months Up to December 2023 | |
| 197. | 0209 | Alternative Dosing And Prevention of Transfusion (ADAPT): A prospective study to reduce transfusion requirements for children for children with sickle cell anemia using pharmacokinetics-based hydroxyurea dosing | 5/26/2022 | Assoc Prof. Robert O. Opoka | Makerere University College of Health Sciences (MUCHS) | Cincinnati’s Children’s Hospital Medical Center | Ongoing | 36 Months | |
| 198. | 0210 | Exposure-Response Evaluation of IV Artesunate in Children with Severe Malaria | 9/14/2022 | Prof. Pauline Byakika-Kibwika | Department of Medicine | VTEU Contract HHSN2722013000221/IDI | Ongoing | 12 Months | |
| 199. | 0211 | Ivermectin-Artemisinin Combination Therapy For Eradication Of Malaria (IVIME) | 8/1/2022 | Prof Jackson Mukonzo | Department of Pharmacology and Therapeutics | MaKRIF | Ongoing | 6 Months | |
| 200. | 0212 | A placebo controlled clinical trial investigating the safety and immunogenicity of GBS6 in pregnant women with and without human immunodeficiency virus (HIV) infection and their infants. | 6/29/2022 | Dr. Musa Sekikubo | MUCHS | St George’s University of London (SGUL) | Ongoing | 24 Months | |
| 201. | 0214 | Simplified Treatment for Eclampsia Prevention using Magnesium sulfate: A phase III, randomized, open label, active controlled, multicountry, andomized, non-inferiority trial of simplified magnesium sulfate regimen for eclampsia prophylaxis (The STEP-Mag Trial) | 2/7/2023 | Dr. Nakalembe Miriam | MUCHS | HRP- The UNDP/UNFPA/UNICEF/WHO/World Bank Special | Ongoing | 48 months | |
| 202. | 0215 | A Phase III Randomized Double-Blind, Placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant Atezolizumab or placebo and Trastuzimab Emtansine for HERS-Positive breast cancer at high risk of recurrence following preoperative therapy. (ASTEFANIA) | 9/21/2022 | Dr. Nixon Niyonzima | Uganda Cancer Institute | F.Hoffmann-LA Roche AG | Ongoing | 14 Years | |
| 203. | 0216 | A Phase III, Randomized, Open-label, Multicenter study andomized the efficacy and safety of adjuvant Giredestrant compared with physician’s choice adjuvant Endocrine monotherapy in patients with Estrogen receptor-positive HERS2-Negative Early Breast Cancer | 11/7/2022 | Dr. Jackson Orem | Uganda Cancer Institute | F.Hoffmann-LA Roche AG | Ongoing | 10 Years | |
| 204. | 0218 | A phase Ib study to assess the safety and immunogenicity of a recombinant adenovirus-based vaccine against plague in Uganda | 12/12/2022 | Dr. Eugene Ruzagira | MRC/UVRI/LSHTM Uganda Research Unit | University of Oxford | Ongoing | 12 Months | |
| 205. | 0219 | A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer. (GO42784) | 11/18/2022 | Dr. Fred Okuku | St. Francis Hospital, Nsambya | F.Hoffman-La Roche Ltd | Ongoing | 10 Years | |
| 206. | 0220 | Extension of SEARCH SAPPHIRE Dynamic Choice Prevention Study. (SEARCH SAPPHIRE) | 11/29/2022 | Prof. Moses R. Kamya | Department of Medicine, Makerere University | University of California, San Francisco | Ongoing | 12 Months | |
| 207. | 0221 | Phase Iia Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 plus Pyronaridine Administered Once Daily for 1 or 2 Days to Adults and Adolescents with Acute Uncomplicated Plasmodium Falciparum Malaria. (M5717) | 11/28/2022 | Dr. Adoke Yeka | Infectious Diseases Research Collaboration (IDRC) | Merck Healthcare KgaA, Darmstadt, Germany, an affiliate of Merck KgaA, Darmstadt, Germany Frankfurter Str. 250 64293 Darmstadt, Germany | Ongoing | 25 Months | |
| 208. | 0222 | “Long-Acting Treatment in Adolescents (LATA) – A andomized open label 2-arm 96-week trial in virologically suppressed HIV-1-positive adolescents aged 12-19 years of age in Sub-Saharan Africa.” | 4/20/2023 | Dr. Adeodata R. Kekitiinwa | Baylor College of Medicine Children’s Foundation-Uganda | University College of London | Ongoing | 60 Months | |
| 209. | 0223 | A Phase Ib trial to evaluate the safety and immunogenicity of R21/Matrix-MTM in African children living with HIV (VAC092) | 10/25/2022 | Dr. Eugene Ruzagira | MRC/UVRI and LSHTM Uganda Research Unit. | Jenner Institute, University of Oxford | Ongoing | 24 Months | |
| 210. | 0224 | Efficacy, Safety and Effectiveness of Injectable Cabotegravir/Rilpivirine in Improving HIV-1 Control in Sub-Saharan Africa: A Pragmatic Phase 3b Open-Label Randomized Controlled Trial. (IMPALA) | 11/7/2022 | Dr. Eugene Ruzagira | MRC/UVRI and LSHTM Uganda Research Unit | London School of Hygiene and Tropical Medicine through MRC/UVRI & LSHTM Uganda Research Unit | Ongoing | 36 Months | |
| 211. | 0226 | A Phase II Multicenter Study of Pomalidomide Monotherapathy in HIV-Positive Individuals with Kaposis Sarcoma (KS) in Sub-Saharan Africa (SSA) | 2/2/2023 | Dr. Jackson Orem | Uganda Cancer Institute (UCI) | AIDS Malignancy Consortium (AMC) | Ongoing | 48 Months | |
| 212. | 0227 | “An adaptive, randomized, active-controlled, open-label, sequential cohort, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of intravenous cipargamin (KAE609) in adult and paediatric participants with severe Plasmodium falciparum malaria (KARISMA – KAE609’s Role in Severe Malaria)” | 8/21/2023 | Dr Adoke Yeka | Infectious Diseases Research Collaboration | Novartis Pharma AG | Ongoing | 24 Months | |
| 213. | 0228 | REMDESIVIR: Monitored Emergency Use for Filovirus Disease | 11/7/2022 | Dr. Olaro Charles | Ministry of Health, Uganda | Ministry of Health, Uganda | Ongoing | ||
| 214. | 0230 | Efficacy And Safety of Dihydroartemisinin-Piperaquine (Eurartesim) For Treatment of Uncomplicated P. Falciparum Malaria In Adult Patients With Covid-19 Co-Morbidity: An Open Label Non-Randomised Clinical Trial (EMCOS CLINICAL TRIAL) | 12/1/2022 | Dr. Haruna Muwonge | Makerere University Lung Institute | Makerere University Lung Institute (MLI) | Ongoing | 12 Months | |
| 215. | 0231 | Safety, Pharmacokinetics and Preliminary Efficacy of Herbal Products for the Treatment of Acute Respiratory Viral Infections Including SARS-COV2 in Uganda; Phase 2A Open Label Clinical Trial (CONAT) | 1/23/2023 | Assoc. Prof. Bruce Kirenga | Makerere University Lung Institute (MLI) | Ministry of Science, Technology and Innovation (MOSTI), Office of the President | Ongoing | 24 Months | |
| 216. | 0232 | Core protocol: Ring Vaccination Trial to Evaluate the Efficacy and Safety of Sudan Ebolavirus Vaccines In Uganda. (TEV/SOLIDARITY) | 11/25/2022 | Assoc. Prof. Bruce Kirenga | Makerere University Lung Institute | Ministry of Health | Ongoing | ||
| 217. | 0233 | A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the prevention of COVID-19 in Participants Aged 18 Years and Older (LVRNA009 | 11/28/2022 | Dr. Francis Kiweewa | Lira Regional Referral Hospital (SICRA) | AIM Vaccine Co. Ltd | Terminated | 24 Months | |
| 218. | 0234 | A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 (ACTIV-2d/A5407) | 3/15/2023 | Dr. Afizi Kibuuka | IDRC Clinic Tororo General Hospital | Shionogi B.V | Ongoing | 24 Months | |
| 219. | 0235 | Cluster andomized controlled trial of a complex intervention package to reduce blindness from severe microbial keratitis in Uganda. | 3/14/2023 | Dr. Arunga Simon | Mbarara University and Referral Hospital Eye Center | London School of Hygiene and Tropical Medicine | Ongoing | 24 Months | |
| 220. | 0236 | “A Phase 2C Clinical Trial of Novel, Short-course Regimens for the Treatment of Pulmonary Tuberculosis: CRUSH-TB (Combination Regimens for Shortening Tbtreatment).” | 4/11/2023 | Prof. Harriet Mayanja-Kizza | Uganda-CWRU Research Collaboration | U.S Centers for Disease Control and Prevention (CDC) | Ongoing | 60 Months | |
| 221. | 0237 | “Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections” | 6/27/2023 | Dr. Joseph Lutaakome | MRC/UVRI and LSHTM Uganda Research Unit | University of Minnesota | Ongoing | ||
| 222. | 0238 | Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age, IMPAACT 2036: | 11/7/2023 | Dr Victoria Ndyanabangi | Baylor College of Medicine Children’s Foundation Uganda | National Institute of Allergy and Infectious Diseases Eunice Kennedy Shriver National of Child Health and Human Development National Institute of Mental Health | Ongoing | 42 Months | |
| 223. | 0239 | A multi-part, multi-center PLATform study to assess the efficacy, safety, tolerability and pharmacokinetics of anti-malarial agents administered as monotherapy and/or combination therapy IN patients with Uncomplicated Plasmodium falciparum Malaria. | 10/5/2023 | Dr. Adoke Yeka | Infectious Diseases Research Collaboration | Norvatis Pharma AG. | Ongoing | 24 Months | |
| 224. | 0240 | Dihydroartemisinin-piperaquine and azithromycin for the post-discharge management of children with severe anaemia in Malawi, Kenya and Uganda; A, andomized, parallel-group, two-arm, andomized, double-blind superiority trial.(PDMC-II) | 6/1/2023 | Assoc. Prof. Richard Idro | Makerere University College of Health Sciences | Training and Research Unit of Excellence (TRUE). | Ongoing | 36 Months | |
| 225. | 0242 | A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety and Antiviral Activity of the GS9883 /Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Adolescents and Children. | 6/26/2023 | Dr Peter James Elyanu | Baylor College of Medicine Children’s Foundation-Uganda | Gilead Sciences Inc. | Ongoing | 96 Weeks | |
| 226. | 0243 | A Phase 2/3 Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK) and efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants (GS-US-216-0218) | 6/16/2023 | Dr Flavia Matovu Kiweewa | MU-JHU Research Collaboration (MU-JHU CARE LTD) | Gilead Sciences Inc. | Ongoing | 30 Months | |
| 227. | 0244 | Gabapentin to Reduce Alcohol and Improve Viral Load Suppression (GRAIL) –Promoting “Treatment as Prevention” | 8/3/2023 | Dr. Winnie Muyindike | Mbarara University of Science and Technology/Regional Referral Hospital. | Jeffrey Samet (Sponsor representative) | Ongoing | 60 Months | |
| 228. | 0245 | Intramuscular vs Enteral Penicillin Prophylaxis to Prevent Progression of Latent Rheumatic Heart Disease: A non-inferiority randomized trial (GOALIE). | 9/22/2023 | Dr. Joselyn Rwebembera | Uganda Heart Institute | National Institute of Health | Ongoing | 48 Months | |
| 229. | 0246 | A multiple arm, multiple stage (MAMS), phase 2B/C, open label, randomized controlled platform trial to evaluate experimental arms including an increased dose of rifampicin, an optimized dose of pyrazinamide, moxifloxacin and sutezolid, in adult subjects with newly diagnosed, smear-positive pulmonary tuberculosis”. | 7/11/2023 | Assoc. Prof. Bruce Kirenga | Makerere University Lung Institute | LMU Klinikum Muenchen, Division of Infectious Diseases and Tropical Medicine | Ongoing | 36 Months | |
| 230. | 0247 | Evaluating Tumor Evolution And The Clinical Utility Of Circulating Tumor Dna In Patients With Metastatic Breast Cancer Treated With Talazoparib.” | 8/8/2023 | Dr. Nixon Niyonzima | Uganda Cancer Institute (UCI) | Uganda Cancer Institute | Ongoing | 24 Months | |
| 231. | 0248 | A phase 2, partially-blinded, randomized trial assessing the safety and efficacy of TBAJ876 or bedaquiline, in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis | 8/9/2023 | Prof Harriet Mayanja-Kizza | Uganda Case Western Reserve University Research Collaboration | TB Alliance | Ongoing | 48 Months | |
| 232. | 0249 | A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults Short Title: Sabin 002, | 7/28/2023 | Dr. Betty Mwesigwa | Makerere University Walter Reed Project | Sabin Vaccine Institute. | Ongoing | 48 Months | |
| 233. | 0250 | Earlier prime-BOOST schedule to improve Measles protection in high burden settings (BoostME) | 10/13/2023 | Dr. Ezekiel Mupere | Makerere University – John Hopkins University Research Collaboration | University of Oxford | Ongoing | 36 Months | |
| 234. | 0251 | A5394: Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HbsAg in Participants with Both Chronic Hepatitis B and HIV. | 11/24/2023 | Dr. Francis Ssali | Joint Clinical Research, | The National Institute of Allergy and Infectious Diseases DAIDS,NIAID, NIH. | Ongoing | 30 Months | |
| 235. | 0252 | A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety and Antiviral Activity of the GS 9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Adolescents and Children. | 7/14/2023 | Dr Flavia Matovu Kiweewa | MU-JHU Research Collaboration | Gilead Sciences Inc. | Ongoing | 96 weeks | |
| 236. | 0253 | A andomized, double blinded, placebo-controlled, multi-centre trial of azithromycin prophylaxis for advanced HIV disease. “Reducing Mortality InAdults With Advanced HIV Disease”. | 10/2/2023 | Dr. Conrad K. Muzoora | Mbarara University | Population Health Research Institute (PHRI) | Ongoing | 60 Months | |
| 237. | 0254 | “A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Ad26.Mos4.HIV and CH505 TF chTrimer (Env) Combination to Mimic Acute HIV Viral Replication Kinetics in Healthy Adults.” | 11/9/2023 | Dr. Grace Mirembe | Makerere University Walter Reed Project | Emily D. Badraslioglu (Acting Representative), The Surgeon General, Department of the Army | Ongoing | 24 Months | |
| 238. | 0255 | “, Hydroxyurea – Pragmatic Reduction In Mortality and Economic burden, H-PRIME | 10/19/2023 | Prof. Peter Olupot-Olupot | Mbale Clinical Research Institute | Imperial College of London | Ongoing | 60 Months | |
| 239. | 0256 | “Platform Assessing Regimens And Durations In a Global Multisite consortium for TB: A seamless Phase 2B/2C platform trial to evaluate multiple regimens and durations of treatment in pulmonary tuberculosis | 4/11/2024 | Dr. Cissy Kityo | Joint Clinical Research Centre | University College London, Institute of Clinical Trials andmethodology | Ongoing | 60 Months | |
| 240. | 0257 | “Master Protocol for Early Treatment and Post-Exposure Prophylaxis of COVID-19 Adaptive Platform Trial and Appendix C entitled “A phase 2 safety and efficacy study of Upamostat for early outpatient treatment of COVID-19”. | 8/1/2024 | Dr. Hannah Kibuuka | Makerere University Walter Reed Project | FHI Clinical | Ongoing | 18 Months | |
| 241. | 0258 | “A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination with Phesgo Versus Phesgo After Induction Therapy with Phesgo+Taxane in Patients with Previously Untreated Her2- Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer.” | 12/11/2023 | Dr. Nixon Niyonzima | Uganda Cancer Institute (UCI), | F. Hoffmann-La Roche LTD | Ongoing | 108 Months | |
| 242. | 0259 | “Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis, | 3/19/2024 | Assoc Prof. David Meya | Infectious Diseases Institute | Assoc Prof. David Meya | Ongoing | 12 Months | |
| 243. | 0261 | A randomized, open-label, multicenter study to compare efficacy, safety and tolerability of KLU156 with Coartem® in the treatment of uncomplicated Plasmodium falciparum malaria in adults and children ≥5 kg body weight followed by an Extension phase with repeated KLU 156 treatment, | 7/29/2024 | Dr Adoke Yeka | Infectious Disease Research Collaboration | Novartis Pharma AG | Ongoing | 36 Months | |
| 244. | 0262 | Six weeks of daily rifapentine vs. a comparator arm of 12-16-week rifamycin- based treatment of latent M. tuberculosis infection: assessment of safety, tolerability and effectiveness | 4/11/2024 | Prof. Harriet Mayanja-Kizza | Uganda-CWRU Research Collaboration | U.S. Centers for Disease Control and Prevention (CDC) TBTC Division of TB Elimination US CDC | Ongoing | 72 Months | |
| 245. | 0263 | “A Phase 2/3 Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety and Efficacy of Cobicistat-boosted Atazanavir(ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants | 3/5/2024 | Dr Flavia Matovu Kiweewa | MU-JHU Research Collaboration (MU-JHU CARE LTD) | Gilead Sciences, Inc. | Ongoing | 60 Months | |
| 246. | 0265 | A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults. | 4/11/2024 | Dr. Betty Mwesigwa | Makerere University Walter Reed Project | Sabin Vaccine Institute. | Ongoing | 60 Months | |
| 247. | 0267 | Effectiveness and Safety Dosing of Sodium Bicarbonate in Women with Obstructed Labor in Eastern Uganda: A Phase III Randomized placebo-controlled Trial (SoBicOL- II Study) | 7/10/2024 | Associate Prof Milton Musaba Wamboko | Busitema University/Mbale Regional Referral Hospital, Uganda. | Busitema University | Ongoing | 24 Months | |
| 248. | 0269 | Zinc for Infection Prevention in Sickle Cell Anemia – 2 (ZIPS-2). | 9/17/2024 | Dr Ruth Namazzi | Department of paediatrics and child health Makerere University College of Health Sciences | Indiana University | Ongoing | 12 Months | |
| 249. | 0270 | Characterization of tuberculosis associated lung fibrosis and respiratory impairment, and prevention using doxycycline in a double blind randomized controlled trial, | 6/21/2024 | Dr Ahmed Ddungu | Makerere University Lung Institute | Makerere University Lung Institute | Ongoing | 24 Months | |
| 250. | 0271 | “Long-Term Follow-Up of CAB LA for Participants in HPTN 083 and HPTN 084 CAB PrEP Studies at Risk of HIV Acquisition.” | 9/19/2024 | Dr. Patricia Nahirya Ntege | Baylor College of Medicine Children’s Foundation Uganda | ViiV Healthcare UK Limited | Ongoing | 36 Months | |
| 251. | 0272 | Pharmacokinetic study of an optimized dose ratio of dolutegravir/ emtricitabine/ tenofovir alafenamide fumarate: expediting a UNIVERSAL first line regimen for all children living with HIV in Africa. | 9/9/2024 | Dr. Grace Paul Kisitu | Baylor Foundation Uganda | PENTA Foundation | Ongoing | 24 Months | |
| 252. | 0273 | Therapeutic Drug Monitoring for Antimicrobial Agents for People Living with HIV (TAP trial) | 8/15/2024 | Dr. Christine Sekaggya –Wiltshire | Infectious Diseases Institute | Infectious Diseases Institute | Ongoing | 24 Months | |
| 253. | 0275 | “Shortened RegiMen for Drug-susceptIbLE TB in Children (SMILE-TB)” | 8/30/2024 | Dr Eric Wobudeya | MU-JHU CARE LTD/ MU-JHU Research Collaboration | Johns Hopkins University School of Medicine | Ongoing | 36 Months | |
Abbreviation
| MUCHS | Makerere University College of Health Sciences |
| MU-JHU | Makerere University – John Hopkins University |
| MU-UCSF | Makerere University – University of California, San Francisco |
| MRC/UVRI | Medical Research Council / Uganda Virus Research Institute |
| UVRI-IAVI | Uganda Virus Research Institute – International AIDS Vaccine Initiative |
| LSHTM | London School of Hygiene and Tropical Medicine |
| MUST | Mbarara University of Science and Technology |
| MUWRP | Makerere University Walter Reed Project |
| CWRURC | Case Western Reserve University Research Collaboration |
| IDI | Infectious Disease Research Collaboration |
| MOH | Ministry of Health Uganda |
| NIAID | National Institute of Allergy and Infectious Diseases |
| NIH | National Institute of Health |
| MAKRIF | Makerere University Research Innovation Fund |
| UCI | Uganda Cancer Institute |
